Code | CSB-E04760h |
Size | 96T |
Price | Request a Quote or Start an on-line Chat |
Trial Size |
24T ELISA Kit Trial Size (Only USD$150/ kit) * The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now |
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||
To assess the linearity of the assay, samples were spiked with high concentrations of human VEGF-D in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||
Sample | Serum(n=4) | |||||
1:1 | Average % | 95 | ||||
Range % | 88-98 | |||||
1:2 | Average % | 102 | ||||
Range % | 92-106 | |||||
1:4 | Average % | 98 | ||||
Range % | 89-102 | |||||
1:8 | Average % | 94 | ||||
Range % | 87-98 |
The recovery of human VEGF-D spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||
Sample Type | Average % Recovery | Range | ||||
Serum (n=5) | 91 | 84-96 | ||||
EDTA plasma (n=4) | 99 | 91-103 | ||||
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The human VEGFD ELISA Kit is intended to measure human VEGFD in serum, plasma, or tissue homogenates. This assay uses the bi-antibody sandwich technique and enzyme-substrate chromogenic reaction to quantify human VEGFD concentration. The intensity of the colored product is directly proportional to the concentration of VEGFD present in the sample. This human VEGFD ELISA kit has high specificity and excellent sensitivity.
VEGFD is a secreted glycoprotein that can activate VEGFR-2 and VEGFR-3 on the endothelium and acts as a mitogen for endothelial cells to promote the growth and remodeling of blood vessels and lymphatic vessels. VEGFD is a potential biomarker for lymphangioleiomyomatosis. It has been demonstrated that high serum levels of VEGFD are linked to atrial fibrillation, ischemic stroke, and heart failure. Elevated VEGFD values have recently been associated with all-cause mortality in individuals with coronary artery disease.
There are currently no reviews for this product.